FdaApplication
BLA 101094
Identifiers
- fda_app_no: BLA101094
Properties
| Property | Value |
|---|---|
| applicant_name | Merck Sharp & Dohme LLC |
| application_type | BLA |
| approval_date | 1977-11-21 |
Revenue by product
PNEUMOVAX 23
| Period | Revenue |
|---|---|
| Q4 2025 | $42.0M |
| Q3 2025 | $45.0M |
| Q2 2025 | $38.0M |
| Q1 2025 | $41.0M |
| Q4 2024 | $75.0M |
| Q3 2024 | $68.0M |
| Q2 2024 | $59.0M |
| Q1 2024 | $61.0M |
| Q4 2023 | $85.0M |
| Q3 2023 | $140.0M |
| Q2 2023 | $92.0M |
| Q1 2023 | $96.0M |
| Q4 2022 | $145.0M |
| Q3 2022 | $131.0M |
| Q2 2022 | $153.0M |
| Q1 2022 | $173.0M |
| Q4 2021 | $293.0M |
| Q3 2021 | $277.0M |
| Q2 2021 | $152.0M |
| Q1 2021 | $171.0M |
| Q4 2020 | $339.0M |
| Q3 2020 | $375.0M |
| Q2 2020 | $117.0M |
| Q1 2020 | $256.0M |
| Q4 2019 | $334.0M |
| Q3 2019 | $237.0M |
| Q2 2019 | $170.0M |
| Q1 2019 | $185.0M |
| Q4 2018 | $321.0M |
| Q3 2018 | $214.0M |
| Q2 2018 | $193.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PNEUMOVAX 23 | — | 25UG/.5ML | Injection |
| PNEUMOVAX 23 | — | 25UG/.5ML | Injection |
2 products